Butylphthalide plus tenecteplase for mild disabling stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether adding butylphthalide (a drug that improves blood flow) to the standard clot-busting medicine tenecteplase can help people with mild but disabling strokes recover better. If you have had a mild stroke within the last 4.5 hours and are 18–80, this study might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- Your stroke symptoms (like arm weakness or trouble talking) started less than 4.5 hours ago.
- Your stroke is mild but still limits your ability to move one side or speak – rated between 2 and 5 on a stroke scale.
- You were able to do daily activities on your own before this stroke (no major disability).
- You are willing and able to sign a consent form for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called butylphthalide helps with long-term recovery after a mild stroke. It might improve thinking and memory over time.
This trial tests whether butylphthalide, given after a procedure to remove a blood clot from the brain, can help reduce dangerous brain swelling. If you've had a severe stroke and recently had a clot-removal procedure, this drug might improve your recovery.
This trial tests a precise treatment to restore blood flow in people who had a mild but disabling stroke up to 24 hours earlier, using mechanical clot removal or clot-busting medication. The goal is to reduce long-term disability by reopening the blocked vessel while protecting healthy brain tissue.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.
This trial tests a clot-busting drug called tenecteplase for patients having a mild stroke (with weakness on one side or trouble speaking) who can get treatment within 4.5 hours. The goal is to see if this drug helps improve blood flow and reduces disability.
Hear when a new Mild Disabling Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.